mhurhangee/patent-ind-claim-en huggingface dataset:
Suspension bearing ring (10, 10', 10") for a motor vehicle suspension, preferably for a car, comprising: - an outer part , - an inner part (20, 20', 20"), - an elastomeric body connecting the inner part and the outer part (20, 20', 20"), in which the inner part (20, 20', 20") includes an inner portion (20B, 20B', 20B"), an outer portion (20A, 20A', 20A") and at least one connection device (20C, 20C', 20C"), - the inner portion (20B, 20B', 20B") comprising a through hole extending in an axial direction (X) and configured to receive a bolt or equivalent , - the outer portion (20A, 20A', 20A") delimiting a space (E) extending in the axial direction (X), - the inner portion (20B, 20B', 20B") extending axially wholly or partly in the space (E) and being coupled to the outer portion (20A, 20A', 20A") by means of the at least one connection device (20C, 20C', 20C"), characterised in that the at least one connection device (20C, 20C', 20C") comprises a fuse portion (20C2, 20C1', 20C") configured to break when the ring (10, 10', 10") is subjected to a predetermined force (F), and a clearance (J) is provided between the inner portion (20B, 20B', 20B") and the outer portion (20A, 20A', 20A") so that the inner portion (20B, 20B', 20B") can move in relation to the outer portion (20A, 20A', 20A") when the fuse portion (20C2, 20C1', 20C") is broken. - an outer part , - an inner part (20, 20', 20"), - an elastomeric body connecting the inner part and the outer part (20, 20', 20"), in which the inner part (20, 20', 20") includes an inner portion (20B, 20B', 20B"), an outer portion (20A, 20A', 20A") and at least one connection device (20C, 20C', 20C"), - the inner portion (20B, 20B', 20B") comprising a through hole extending in an axial direction (X) and configured to receive a bolt or equivalent , - the outer portion (20A, 20A', 20A") delimiting a space (E) extending in the axial direction (X), - the inner portion (20B, 20B', 20B") extending axially wholly or partly in the space (E) and being coupled to the outer portion (20A, 20A', 20A") by means of the at least one connection device (20C, 20C', 20C"), characterised in that
A cannula insertion device comprising: a first carriage comprising a cannula; a yoke fixed in an inertial frame of reference, the yoke comprising a channel ; a linkage rotatably connected to the first carriage and comprising a post positioned in the channel of the yoke , whereby the post slides left and right in the channel , when the linkage rotates; a torsion spring comprising two legs, one attached to the linkage ; and a locking device for locking the spring in tension, the first carriage , and the linkage prior to activation; wherein the first carriage is slidable in a direction perpendicular to an infusion site, further comprising a second carriage positioned below the first carriage , wherein the second carriage comprises a catheter . wherein upon release of the locking device , the tension of the spring is released to cause the linkage to move in the channel and slide the first carriage toward an infusion site. a first carriage comprising a cannula; a yoke fixed in an inertial frame of reference, the yoke comprising a channel ; a linkage rotatably connected to the first carriage and comprising a post positioned in the channel of the yoke , whereby the post slides left and right in the channel , when the linkage rotates; a torsion spring comprising two legs, one attached to the linkage ; and a locking device for locking the spring in tension, the first carriage , and the linkage prior to activation; wherein the first carriage is slidable in a direction perpendicular to an infusion site, further comprising a second carriage positioned below the first carriage , wherein the second carriage comprises a catheter . wherein upon release of the locking device , the tension of the spring is released to cause the linkage to move in the channel and slide the first carriage toward an infusion site.
A method of a terminal in a wireless communication system, the method comprising: receiving, from a primary cell, a signal by using a first RF chain; receiving, from a secondary cell, a signal by using at least one of a plurality of RF chains different from the first RF chain; receiving, from the primary cell, a message for a handover including an indicator indicating whether a plurality of RF chains can be used for the handover; wherein in case that the indicator indicates that a plurality of RF chains can be used for handover the method further comprises: deactivating the secondary cell; identifying a second RF chain supporting a frequency of a target cell among the plurality of RF chains; performing a synchronization with the target cell by using the second RF chain while transmitting and receiving a signal to and from the primary cell by using the first RF chain; receiving, from the target cell, a signal by using the second RF chain after performing the synchronization. receiving, from a primary cell, a signal by using a first RF chain; receiving, from a secondary cell, a signal by using at least one of a plurality of RF chains different from the first RF chain; receiving, from the primary cell, a message for a handover including an indicator indicating whether a plurality of RF chains can be used for the handover; wherein in case that the indicator indicates that a plurality of RF chains can be used for handover the method further comprises: deactivating the secondary cell; identifying a second RF chain supporting a frequency of a target cell among the plurality of RF chains; performing a synchronization with the target cell by using the second RF chain while transmitting and receiving a signal to and from the primary cell by using the first RF chain; receiving, from the target cell, a signal by using the second RF chain after performing the synchronization.
A pneumatic tire comprising: a pattern on a surface of a sidewall , wherein the pattern has a plurality of annular figures that are longer in a tire circumferential direction (CD) than in a tire radial direction (RD), and the plural annular figures have different sizes from one another, which are arranged so that a larger annular figure is placed on an outer side of a smaller annular figure without crossing each other, and so that intervals of the annular figures differ on one side and the other side in the tire circumferential direction. a pattern on a surface of a sidewall , wherein the pattern has a plurality of annular figures that are longer in a tire circumferential direction (CD) than in a tire radial direction (RD), and the plural annular figures have different sizes from one another, which are arranged so that a larger annular figure is placed on an outer side of a smaller annular figure without crossing each other, and so that intervals of the annular figures differ on one side and the other side in the tire circumferential direction.
A method performed by a terminal in a wireless communication system, the method comprising: identifying whether a maximum number of retransmissions, for a packet, associated with a radio link control, RLC, entity is reached (2e-10); identifying whether a packet duplication is activated and a list of a usable cell for a logical channel corresponding to the RLC entity neither includes a primary cell, PCell, nor a primary secondary cell, PSCell (2e-10, 2e-20); in case that the maximum number of retransmissions associated with the RLC entity is reached, the packet duplication is activated and the list of the usable cell for the logical channel corresponding to the RLC entity neither includes the PCell nor the PSCell, transmitting, by a radio resource control, RRC, entity, to a base station, a report message indicating the RLC entity having an error, and wherein the report message indicating the RLC entity having an error includes information on an identity, ID, of the logical channel for the RLC entity and information on a cell group associated with the RLC entity, and wherein a radio link failure, RLF, procedure for the cell group associated with the RLC entity is performed in case that the packet duplication is deactivated, the maximum number of retransmissions associated with the RLC entity is reached and the list of the usable cell for the logical channel corresponding to the RLC entity neither includes the PCell nor the PSCell. identifying whether a maximum number of retransmissions, for a packet, associated with a radio link control, RLC, entity is reached (2e-10); identifying whether a packet duplication is activated and a list of a usable cell for a logical channel corresponding to the RLC entity neither includes a primary cell, PCell, nor a primary secondary cell, PSCell (2e-10, 2e-20); in case that the maximum number of retransmissions associated with the RLC entity is reached, the packet duplication is activated and the list of the usable cell for the logical channel corresponding to the RLC entity neither includes the PCell nor the PSCell, transmitting, by a radio resource control, RRC, entity, to a base station, a report message indicating the RLC entity having an error, and wherein the report message indicating the RLC entity having an error includes information on an identity, ID, of the logical channel for the RLC entity and information on a cell group associated with the RLC entity, and wherein a radio link failure, RLF, procedure for the cell group associated with the RLC entity is performed in case that the packet duplication is deactivated, the maximum number of retransmissions associated with the RLC entity is reached and the list of the usable cell for the logical channel corresponding to the RLC entity neither includes the PCell nor the PSCell.
A compound for use in a method of treating cystic fibrosis, wherein said compound is an inhibitor of a TMEM16 protein, preferably of TMEM16A and/or TMEM16F, and wherein said compound is selected from a structure of Formula I: wherein R 1 is selected from the group consisting of substituted or unsubstituted aryl or heteroaryl, preferably substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, amino, nitro, cyano, thiol, sulfonyl, carbonyl, carboxyl, alkyl, alkoxy, acetoxy, alkenyl, cycloalkyl, aryl, and heteroaryl, wherein it is preferably substituted or unsubstituted phenyl, more preferably phenyl substituted with one or more substituents selected from hydroxyl, halogen, and acetoxy, wherein R 2 is selected from the group consisting of substituted or unsubstituted aryl or heteroaryl, preferably substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, amino, nitro, cyano, thiol, sulfonyl, carbonyl, carboxyl, alkyl, alkoxy, acetoxy, alkenyl, cycloalkyl, aryl, and heteroaryl, wherein it is preferably selected from thiazolyl and phenyl, more preferably thiazolyl and phenyl substituted with halogen, or a pharmaceutically acceptable salt thereof. wherein R 1 is selected from the group consisting of substituted or unsubstituted aryl or heteroaryl, preferably substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, amino, nitro, cyano, thiol, sulfonyl, carbonyl, carboxyl, alkyl, alkoxy, acetoxy, alkenyl, cycloalkyl, aryl, and heteroaryl, wherein it is preferably substituted or unsubstituted phenyl, more preferably phenyl substituted with one or more substituents selected from hydroxyl, halogen, and acetoxy, wherein R 2 is selected from the group consisting of substituted or unsubstituted aryl or heteroaryl, preferably substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, amino, nitro, cyano, thiol, sulfonyl, carbonyl, carboxyl, alkyl, alkoxy, acetoxy, alkenyl, cycloalkyl, aryl, and heteroaryl, wherein it is preferably selected from thiazolyl and phenyl, more preferably thiazolyl and phenyl substituted with halogen, or a pharmaceutically acceptable salt thereof.
A method of operating a gas turbine engine of an aircraft, the method comprising: receiving fuel; supplying a first portion of the fuel to a combustor of the gas turbine engine via a first fuel manifold ; supplying a second portion of the fuel to the combustor of the gas turbine engine via a second fuel manifold ; supplying a third portion of the fuel to a reservoir ; stopping fuel supply to the combustor via the first and second fuel manifolds , the first fuel manifold containing first residual fuel and the second fuel manifold containing second residual fuel; and after stopping fuel supply to the combustor via the first and second fuel manifolds : receiving the second residual fuel purged from the second fuel manifold into the reservoir ; driving the third portion of the fuel out of the reservoir and using the third portion of the fuel to drive a Venturi pump ; and using the Venturi pump to drive the first residual fuel in the first fuel manifold upstream and purge the first fuel manifold of the first residual fuel. receiving fuel; supplying a first portion of the fuel to a combustor of the gas turbine engine via a first fuel manifold ; supplying a second portion of the fuel to the combustor of the gas turbine engine via a second fuel manifold ; supplying a third portion of the fuel to a reservoir ; stopping fuel supply to the combustor via the first and second fuel manifolds , the first fuel manifold containing first residual fuel and the second fuel manifold containing second residual fuel; and after stopping fuel supply to the combustor via the first and second fuel manifolds : receiving the second residual fuel purged from the second fuel manifold into the reservoir ; driving the third portion of the fuel out of the reservoir and using the third portion of the fuel to drive a Venturi pump ; and using the Venturi pump to drive the first residual fuel in the first fuel manifold upstream and purge the first fuel manifold of the first residual fuel. receiving the second residual fuel purged from the second fuel manifold into the reservoir ; driving the third portion of the fuel out of the reservoir and using the third portion of the fuel to drive a Venturi pump ; and using the Venturi pump to drive the first residual fuel in the first fuel manifold upstream and purge the first fuel manifold of the first residual fuel.
A shelf-life stable fine dry particulate retinal composition that includes a retinaldehyde present inside of the pores of nanoporous calcium particles and/or on the surface of the particles and the particles have diameters that range from 0.01 to 100 μm.
A hammering device for hammering elongated objects into the ground which hammering device comprises a body which can be attached to a power tool, a vibrator device which is attached to the body with damping cushions , and movable gripping jaws which are adjusted to the mentioned vibrator device in order to grip the object to be hammered at least with a side grip wherein the gripping elements of the gripping jaws can be brought closer and farther away with a regulating unit, characterized in that in order to maintain mutual symmetry of the gripping jaws during their movement, the gripping jaws comprise arms , which are rigidly attached to the gripping jaws at the location of the turning joints of the gripping jaws, which arms are directed in such a way that the ends of the arms , are located next to each other and stay essentially next to each other during the turning movements of the gripping jaws , and in that the ends of the mentioned arms ; are connected to each other with a short arm which has a pivot mounting; wherein the arms ; are located and turn at a same level and wherein a distance (d) of centres of pivots of the short arm is under 20 % of a distance (D) of pivots of the gripping jaws .
A chimeric molecule capable of eliciting antibodies against a specific pathogen, said chimeric molecule comprising: a. an immunoglobulin scaffold, wherein said immunoglobulin scaffold comprises two identical immunoglobulin heavy chains and two immunoglobulin light chains comprising variable region domains specific for binding to a protein on an antigen presenting cell, wherein the immunoglobulin heavy chain is IgG2a, and wherein said protein on the antigen presenting cell is selected from the group consisting of CD205, CD11b and CD11c; b. a CD4 T cell costimulatory domain which is: i. linked to one of the heavy chains of said immunoglobulin scaffold via a linker at the C-terminal end of the heavy chain, or ii. connected, via a linker, to the C-terminal end of a pathogen-specific B cell epitope, the pathogen-specific B cell epitope being connected, via a linker to the C-terminal end of the immunoglobulin heavy chain of the immunoglobulin scaffold, and wherein said costimulatory domain is selected from the group consisting of B7.1 (CD80), B7.2 (CD86), Interleukin-2, Interleukin-12, interleukin-4, interleukin-5, interleukin-6, interleukin-10, and interleukin-13; and c. a pathogen-specific CD4 T cell epitope linked at the C-terminal end of a light chain of said immunoglobulin scaffold. a. an immunoglobulin scaffold, wherein said immunoglobulin scaffold comprises two identical immunoglobulin heavy chains and two immunoglobulin light chains comprising variable region domains specific for binding to a protein on an antigen presenting cell, wherein the immunoglobulin heavy chain is IgG2a, and wherein said protein on the antigen presenting cell is selected from the group consisting of CD205, CD11b and CD11c; b. a CD4 T cell costimulatory domain which is: i. linked to one of the heavy chains of said immunoglobulin scaffold via a linker at the C-terminal end of the heavy chain, or ii. connected, via a linker, to the C-terminal end of a pathogen-specific B cell epitope, the pathogen-specific B cell epitope being connected, via a linker to the C-terminal end of the immunoglobulin heavy chain of the immunoglobulin scaffold, and wherein said costimulatory domain is selected from the group consisting of B7.1 (CD80), B7.2 (CD86), Interleukin-2, Interleukin-12, interleukin-4, interleukin-5, interleukin-6, interleukin-10, and interleukin-13; and i. linked to one of the heavy chains of said immunoglobulin scaffold via a linker at the C-terminal end of the heavy chain, or ii. connected, via a linker, to the C-terminal end of a pathogen-specific B cell epitope, the pathogen-specific B cell epitope being connected, via a linker to the C-terminal end of the immunoglobulin heavy chain of the immunoglobulin scaffold, and c. a pathogen-specific CD4 T cell epitope linked at the C-terminal end of a light chain of said immunoglobulin scaffold.
A sunscreen or daily care composition comprising (i) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate); and (ii) 1-(4-(1,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (INCI butyl methoxydibenzoylmethane); and (iii) 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5 triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine); and (iv) 4,4',4"-(1,3,5-triazine-2,4,6-triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone) and/or 4,4'-[[6-[[4-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]amino]-1,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2-ethylhexyl)ester (INCI diethylhexyl-butamidotriazone), wherein the composition is free of 2,2'-methylene bis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol] (INCI methylene bis-benzotriazolyl tetramethylbutylphenol), 2,4,6-tris(biphenyl-4-yl)-1,3,5-triazine (INCI tris-biphenyl triazine), titanium dioxide, zinc oxide and benzylidine malonates according to the following preferred structures: wherein R 1 is methyl, ethyl, propyl or n-butyl; if R 1 is methyl, then R is tert. butyl or a radical of formula or a radical of formula wherein R 2 and R 3 are independently from each other hydrogen or methyl; R 4 is methyl, ethyl or n-propyl; R 5 and R 6 are independently from each other hydrogen or C 1 -C 3 -alkyl; if R 1 is ethyl, propyl or n-butyl, then R is isopropyl; and wherein the composition comprises (i) to (ii) in a ratio of larger or equal to 0.8. (i) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate); and (ii) 1-(4-(1,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (INCI butyl methoxydibenzoylmethane); and (iii) 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5 triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine); and (iv) 4,4',4"-(1,3,5-triazine-2,4,6-triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone) and/or 4,4'-[[6-[[4-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]amino]-1,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2-ethylhexyl)ester (INCI diethylhexyl-butamidotriazone), wherein the composition is free of 2,2'-methylene bis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol] (INCI methylene bis-benzotriazolyl tetramethylbutylphenol), 2,4,6-tris(biphenyl-4-yl)-1,3,5-triazine (INCI tris-biphenyl triazine), titanium dioxide, zinc oxide and benzylidine malonates according to the following preferred structures: wherein R 1 is methyl, ethyl, propyl or n-butyl; if R 1 is methyl, then R is tert. butyl or a radical of formula or a radical of formula wherein R 2 and R 3 are independently from each other hydrogen or methyl; R 4 is methyl, ethyl or n-propyl; R 5 and R 6 are independently from each other hydrogen or C 1 -C 3 -alkyl; if R 1 is ethyl, propyl or n-butyl, then R is isopropyl; and wherein the composition comprises (i) to (ii) in a ratio of larger or equal to 0.8.
A nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide that has pesticidal activity, wherein said nucleotide sequence is selected from the group consisting of: a) the nucleotide sequence of SEQ ID NO: 1 or 60, or a complement thereof; b) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence of SEQ ID NO: 1 or 60, or a complement thereof; c) a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 61; d) a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2 or 61; e) the nucleotide sequence of the DNA insert of the plasmid deposited as Accession No. NRRL B-30961, or a complement thereof a) the nucleotide sequence of SEQ ID NO: 1 or 60, or a complement thereof; b) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence of SEQ ID NO: 1 or 60, or a complement thereof; c) a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 61; d) a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2 or 61; e) the nucleotide sequence of the DNA insert of the plasmid deposited as Accession No. NRRL B-30961, or a complement thereof
Duplex ferritic austenitic stainless steel having 40 - 60 volume % ferrite and 40 - 60 volume % austenite, at the annealed condition, and having improved cold workability and impact toughness, characterized in that the steel, having the impact strength at least 27,5 J, consisting of in weight % less than 0.04 % carbon (C), 0,1 - 2,0 % silicon (Si), 3,8 - 5 % manganese (Mn), 21 - 22 % chromium (Cr), 1,35 - 1,9 % nickel (Ni), 1,1 - 1,5 % copper (Cu), 0.18 - 0,26 % nitrogen (N), optionally molybdenum (Mo) and/or tungsten (W) in a total amount calculated with the formula (Mo + 1⁄2W) ≤ 1,0 %, optionally 0,001 - 0,005 % boron (B), optionally up to 0,03 % of each of cerium (Ce) and/or calcium (Ca), balance being iron (Fe) and inevitable impurities such as Ti, Nb, Co and for the ferrite formers and the austenite formers, i.e. for the chromium equivalent (Cr eq ) and the nickel equivalent (Ni eq ): 21 < Cr eq < 24,5 and Ni eq > 10, where Cr eq = Cr + 1,5Si + Mo + 2Ti + 0,5Nb, Ni eq = Ni + 0,5Mn + 30(C+N) + 0,5(Cu+Co) and the alloys annealed according to the ASTM G150 test with 1,0 M NaCl and the critical pitting temperature (CPT) is 13 - 19 °C.